Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab in prior BCMA-exposed relapsed/refractory multiple myeloma
2023-505865-94-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Oct 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of cevostamab in multiple myeloma (MM) (2 cohorts), sponsored by Roche. Primary endpoints: Objective response rate and Incidence and severity of adverse events. Planned start Oct 2022; status: authorised.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505865-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505865-94-00.